Sanofi-a Ventis Deutschland Gmbh

Sanofi

Werner Mueller

Ulrich Werner

Peter Boderke

Petra Loos

Verena Siefke-Henzler

Anette Brunner-Schwarz

Annika Hagendorf

Gerrit Hauck

Isabell Schoettle

Annke Hahn

Martin Vogel

Christiane Fuerst

Reinhard Becker

Katrin Tertsch

Annke Frick

Matthias Wabl

A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.

Pharmaceutical composition comprising a GLP-1-agonist and methionine

A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.

Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine

A liquid composition comprising a GLP-1 agonist and/or a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivatives where appropriate.

Pharmaceutical composition comprising a GLP-1 agonist and methionine

The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Long-acting formulations of insulin

The present invention relates to a method for the quantitative determination of an impurity present in a peptide product, wherein the impurity cannot be separated from other impurities or the main product. The method particularly involves the use of high resolution mass spectrometry (MS) detection with or without high performance liquid chromatography (HPLC). The method can be used for the investigation of the quality of peptides and proteins, particularly of pharmaceutical peptides and proteins.

Quantification of impurities for release testing of peptide products

Growing community of inventors

Frankfurt am Main, Germany

Werner Mueller